UPDATE: SVB Leerink Upgrades bluebird bio to Outperform, Reiterates $119 Target Notes Co. 'is trading just below our zero B-cell maturation antigen (BCMA) value estimate of $77/share – setting up an attractive risk/reward into BCMA data'